Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer

Condition:   Breast Cancer Female Interventions:   Drug: tamoxifen, letrozole, anastrozole, or exemestane;   Behavioral: Patient reported outcomes Sponsor:   Trish Millard, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

In this study, we evaluated the prevalence of ESR1m in tumor samples from patients with ER+ breast cancer resistant to neoadjuvant aromatase inhibitor therapy.Methods: We followed a prospective cohort of patients with ER+ HER2– stages II and III breast cancer treated with neoadjuvant endocrine therapy (NET). Tumor samples from patients with a pattern of primary endocrine resistance [defined as a Preoperative Endocrine Prognostic Index (PEPI) score of ≥4] were identified and analyzed for the presence of ESR1m.Results: One hundred twenty-seven patients were included in the cohort, of which 100 (79%) had completed NE...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)–targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients with receptor-positive breast cancer subtypes. Preclinical discoveries are needed to identify, develop, and advance new drug targets to improve outcomes for patients with TNBC. Here, we report that MYCN, an oncogene typically overexpressed in tumors of the nervous system or with neuroendocrine features, is heterogeneously exp...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
This study evaluated the time to initiation and completion of treatment in breast cancer patients undergoing neoadjuvant chemotherapy (NAC) vs adjuvant chemotherapy. We found that NAC did not expedite the start or completion of treatment. AbstractBackground/ObjectiveDelays in times to surgery, chemotherapy, and radiotherapy impair survival in breast cancer patients. Neoadjuvant chemotherapy (NAC) confers equivalent survival to adjuvant chemotherapy (AC), but it remains unknown which approach facilitates faster initiation and completion of treatment.MethodsWomen ≥18 years old with nonrecurrent, noninflammatory, clin...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Condition:   Breast Cancer Female Interventions:   Drug: tamoxifen, letrozole, anastrozole, or exemestane;   Behavioral: Patient reported outcomes Sponsor:   Trish Millard, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
British Journal of Cancer, Published online: 31 January 2020; doi:10.1038/s41416-020-0733-xPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Altundag K PMID: 31983142 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen receptor-positive / HER2-negative breast cancer (ER+/HER2- BC)...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
ConclusionsOur findings encourage the continued evaluation of AR antagonists for BC treatment and support that AR pathway activity serves as a better prognostic factor than AR expression in BC.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
Authors: Ding Y, Ding K, Yu K, Zou D, Yang H, He X, Mo W, Yu X, Ding X Abstract The 2010 American Society of Clinical Oncology guidelines have reduced the immunohistochemistry cut-off value for determining estrogen receptor b positivity from 10 to 1% of stained cells in breast cancer. In clinical practice, low-hormone receptor positive (low HR+) tumors are classified in the luminal subtype, although they exhibit aggressive features and poor prognosis. Information regarding the prognosis of patients with breast cancer following treatment with optimal endocrine therapy and neoadjuvant chemotherapy (NAC) is currently ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
AbstractPurpose of ReviewThis review will discuss recent important trials for the treatment of HER2-positive breast cancer, emphasize ongoing areas of development, and highlight areas of unmet need.Recent FindingsAdvances for early-stage treatment have been driven by key clinical trials with pertuzumab, neratinib, and TDM-1. In the adjuvant setting, dual HER2 targeting with trastuzumab and pertuzumab has demonstrated modest improvement in disease-free survival. Neratinib also showed modest benefit in the extended adjuvant setting after prior trastuzumab. Finally, for patients who did not achieve pathologic complete respons...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Geriatrics | Neoadjuvant Therapy | Research | Tamoxifen